Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, is a recalcitrant tumor that is the third leading cause of adult cancer death with a 5-y survival rate below 10% despite significant advances in understanding the genetics and biology of the disease. Cancer cells can adapt by rewiring their metabolism via stimulating nutrient uptake pathways and upregulating rate-limiting enzymes involved in anabolic pathways. PDACs are extremely intractable solid tumors that experience a hypoxic and nutrient-deprived microenvironment and often undergo a metabolic switch to support increased glycolytic flux for their growth.
Fig.1 The contributions of glycogen metabolism to cancer progression. (Khan, et al., 2020)
CD BioGlyco offers a glycogene discovery service in pancreatic cancer. Meanwhile, we exemplify the summary of glycogenes involved in pancreatic cancer.
Fig.2 Glycogene discovery in pancreatic cancer. (CD BioGlyco)
CD BioGlyco dedicates Cancer Glycogene research, providing full-scale custom cancer glycogene discovery services. We are the preferred supplier for clients worldwide. Please feel free to contact us for more information.